BioSpace News Archive

Principia Biopharma Inc. today announced that dosing has been completed for all participants in a Phase 1 clinical trial of PRN2246, a Bruton’s tyrosine kinase (BTK) inhibitor designed to cross the human blood-brain barrier.

Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017.

Jason Boucher Will Assume the Chief Financial Officer Role, Effective October 1, 2018

Orthofix International N.V. announced that it plans to release financial results for the second quarter 2018 after market close on Monday, August 6, 2018.

CBT Pharmaceuticals today announced the continuation of the CBT-501 Phase 1 clinical trial with the initiation of the Phase 1b segment of the study in patients with select advanced or relapsed/recurrent solid tumors.

Puma Biotechnology, Inc. will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 9, 2018 following release of its second quarter 2018 financial results.

bluebird bio, Inc. (Nasdaq: BLUE) today announced that its investigational LentiGlobin™ gene therapy for the treatment of adolescent and adult patients with transfusion-dependent β-thalassemia (TDT) and a non-β0/β0 genotype, was granted an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for its upcoming marketing authorization application (MAA).

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of LifePoint Health, Inc.

Masimo announced the findings of a recently published study in which researchers at Dartmouth-Hitchcock Medical Center investigated the impact of an integrated clinical monitoring system

Company Will Request Hearing with Nasdaq Hearings Panel